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Macrophage migration 
inhibitory factor as a diagnostic 
and predictive biomarker in sepsis: 
meta‑analysis of clinical trials
Janos Toldi1,2, David Nemeth3, Peter Hegyi3, Zsolt Molnar3,4, Margit Solymar1, Nelli Farkas5, 
Hussain Alizadeh6, Zoltan Rumbus1, Eszter Pakai1 & Andras Garami1*
The hunt for useful sepsis biomarkers is ongoing. Macrophage migration inhibitory factor (MIF) was 
implicated as a biomarker in sepsis, but its diagnostic and prognostic value has remained unclear in 
human studies. Here, we aimed at clarifying the value of MIF as a sepsis biomarker with the meta‑
analysis of clinical trials. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials 
databases were searched until December 2019. From the included studies, blood MIF levels and 
indicators of disease severity were extracted in septic and control patient groups. Twenty‑one eligible 
studies were identified, including data from 1876 subjects (of which 1206 had sepsis). In the septic 
patients, blood MIF levels were significantly higher than in healthy controls with a standardized 
mean difference (SMD) of 1.47 (95% confidence interval, CI: 0.96–1.97; p < 0.001) and also higher 
than in patient groups with nonseptic systemic inflammation (SMD = 0.94; CI: 0.51–1.38; p < 0.001). 
Markedly greater elevation in blood MIF level was found in the more severe forms of sepsis and in 
nonsurvivors than in less severe forms and in survivors with SMDs of 0.84 (CI: 0.45–1.24) and  0.75 (CI: 
0.40–1.11), respectively (p < 0.001 for both). In conclusion, blood MIF level is more elevated in systemic 
inflammation caused by infection (i.e., sepsis) compared to noninfectious causes. In more severe 
forms of sepsis, including fatal outcome, MIF levels are higher than in less severe forms. These results 
suggest that MIF can be a valuable diagnostic and prognostic biomarker in sepsis given that well‑
designed clinical trials validate our findings.
Sepsis, a form of systemic inflammation, is defined as life-threatening organ dysfunction caused by dysregu-
lated host response to  infection1. Even nowadays, sepsis and related diseases represent a major challenge for the 
healthcare system. According to a novel analysis of cause-of-death data from 109 million records in the Global 
Burden of Diseases, Injuries, and Risk Factors Study, nearly 49 million incident cases of sepsis could be estimated 
worldwide and 11 million sepsis-related deaths were  reported2. In a cohort from 6 hospitals in the US, sepsis was 
present in more than half of the hospitalizations and accounted for the highest ratio (35%) among the causes of 
 death3. While there was some evidence of a trend towards decreasing mortality rates in septic patients over the 
last decade, a continuous decline in mortality was not observed among patients with sepsis or septic shock in a 
recent systematic  review4. These data warrant for the need of better sepsis management, which could be facilitated 
by improved diagnostic and prognostic tools.
In spite of the desperate need for reliable biomarkers in sepsis, according to the Sepsis-3 definition consensus, 
the novel candidates require further validation before they can be incorporated into the clinical  practice1. In 2010, 
an electronic search identified 178 sepsis-related biomarkers, but none of them was found eligible for routine 
use in clinical  practice5. According to a current review by the same  group6, the list of potential biomarkers in 
sepsis has expanded, and in 2020 it included more than 250 substances, but only a few of them were evaluated 
in a large patient population or in repeated studies, which still limits their clinical usability.
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Macrophage migration inhibitory factor (MIF), a mediator of the innate immune system, is involved in many 
inflammatory processes and related disorders, including obesity and diabetes  mellitus7,8, autoimmune  disorders7,9, 
and  cancer7,10. Besides the role of MIF in chronic inflammation, as a proinflammatory cytokine, it is rapidly 
released into the bloodstream in different forms of acute systemic  inflammation11. The causes of acute systemic 
inflammation can be diverse, including diseases induced by microbial pathogens (e.g., sepsis, septic shock), as 
well as, noninfectious illnesses due to stress, autoimmune reaction, trauma, surgery, burns, etc. Increased blood 
MIF levels were reported in forms of acute systemic inflammation originating from both infectious and noninfec-
tious  etiologies7, but it has remained questionable whether the magnitude of the increase is similar or different 
in the two forms, therefore, if MIF can be used as a diagnostic tool in sepsis. A similar increase in MIF levels was 
observed in patients with systemic inflammation of septic and nonseptic (i.e., caused by major surgery) origin 
compared to the healthy  controls12, suggesting that MIF may serve as a biomarker for critical illness without the 
ability to differentiate between infectious and noninfectious causes. However, in other studies, MIF levels were 
markedly higher in sepsis than in patients with other forms of systemic  inflammation13–15, indicating that MIF 
can be used as a diagnostic biomarker in sepsis.
The prognostic value of MIF has also remained controversial. On the one hand, high serum levels of MIF 
were found in septic patients and even higher MIF levels in patients with septic shock, though the difference was 
not statistically significant (p = 0.3)16. Not significantly higher MIF levels were also reported in septic patients 
with lung complications compared to those without  it13. On the other hand, no significant correlation was 
found between serum MIF levels and sepsis severity or  mortality17. Further complicating the issue, circulating 
MIF levels did not differ between sepsis survivors and nonsurvivors in one  study18, whereas nonsurvivors had 
significantly higher MIF levels in another  study13.
In the present meta-analysis, we aimed at studying the diagnostic and prognostic value of blood MIF levels 
in sepsis by analyzing the currently available published data in humans.
Methods
Our meta-analysis was conducted in accordance with the guidelines of the PRISMA (Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis)  statement19 (Supplementary Table S1). The question of our analysis 
was defined in the PICO [Patients, Indicator, Comparison, Outcome] format: in adult septic patients, we aimed 
at assessing the biomarker role of MIF in the diagnosis and prognosis of the disease. This meta-analysis has been 
registered with PROSPERO (CRD42020139137).
Search strategy. We searched the PubMed, EMBASE, and CENTRAL (Cochrane Central Register of 
Controlled Trials) databases for original human studies without time period limitations. The following search 
term was used: ("macrophage migration inhibitory factor" OR MIF) AND (sepsis OR septic). As in our previ-
ous meta-analysis of  sepsis20, publications reporting immunosuppressive conditions (e.g., transplantation, HIV 
infection) were not included in the current analysis. Similarly to our past  studies20,21, the search was conducted 
separately by two authors (JT, AG), who also assessed study eligibility and extracted data from the selected stud-
ies independently. Disagreements were resolved by consensus, with the help of a third party (ZR).
Study selection, data extraction, and risk of bias assessment. The titles and abstracts of the pub-
lications identified by the literature search were screened, and the full texts of potentially eligible articles were 
obtained. We included studies which reported blood MIF levels in two or more different patient groups, at least 
one of which groups consisted of septic patients. For analysis of the prognostic value, an indication of disease 
severity or outcome (e.g., mortality rate) was also required for the groups. From all included articles we extracted 
the country of origin, characteristics of the patient populations (sample size, sex ratio, age, severity score, mor-
tality), and the reported blood MIF level values of the patient groups with the corresponding indicator of stand-
ard deviation (SD). The extracted values were converted to mean and SD unless specified otherwise. Different 
patient groups within a study (e.g., survivor vs. nonsurvivor, septic vs. nonseptic systemic inflammation) were 
extracted separately.
We assessed the quality of each study included in the meta-analysis by using the Newcastle–Ottawa  Scale22 
(Supplementary Table S2).
Statistical analysis. For each included study, we calculated the difference between the blood MIF level 
of a septic patient group and that of another septic group or a control group. For all groups, the means were 
standardized (based on variances) to obtain standardized mean differences (SMDs). For standardization, the 
means were divided by their corresponding SD values, which was required because the different MIF measuring 
methods could result in different variances among the study groups and influence the results. The SMDs with 
95% confidence intervals (CIs) were calculated by using the random effect model by DerSimonian and  Laird23, 
and then compared using standard meta-analysis tools (i.e., forest plot).
In accordance with the Cochrane Handbook for Systematic  Reviews24, between-study heterogeneity was tested 
with I2 statistical test, where I2 is the proportion of total variation attributable to between-study variability (an I2 
value of more than 50% was considered as an indication of substantial heterogeneity). The presence of publication 
bias was determined by visual inspection of funnel plots (Supplementary Figs. S1-S4) for the lack of asymmetry 
and evaluated quantitatively by Egger’s test (p < 0.1 indicating publication bias). Sensitivity analysis (i.e., iteratively 
omitting one study from the analyses and recalculating SMD to investigate the impact of the individual study 
on the summary estimate) was performed to test the impact of the individual studies. The meta-analyses were 
performed with Comprehensive Meta-Analysis (version 3.3; Biostat, Engelwood, MJ, USA) software.
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A receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic performance of 
blood MIF levels in sepsis. For that, individual blood MIF level data of septic patients and healthy controls were 
extracted with WebPlotDigitizer application from eligible  papers25–27, which presented the data in figures with 
linear scales. The area under the ROC curve (AUC) was calculated to assess the accuracy of blood MIF level 
measurement as a diagnostic test in sepsis. Within the range of 0.5 (no diagnostic ability) to 1.0 (perfect diag-
nostic ability), a higher AUC indicates better performance of a test. ROC curve analysis was performed using 
IBM SPSS Statistics for Windows, version 26 (IBM Corporation, Armonk, NY, USA).
Results
Study selection, characteristics, and quality. The flow chart of the study selection is presented in 
Fig. 1. Until December 2019, the electronic literature search identified altogether 621 studies from the PubMed, 
EMBASE, and CENTRAL databases. After enabling filters for human studies and removal of duplicates, 315 
articles remained, which were screened on title and abstract for inclusion criteria. As a result, the full texts of 45 
articles were obtained, out of which 21 publications were found eligible for statistical  analysis12–18,25–38, including 
data from a total of 1876 human subjects. The studied groups consisted of 1206 septic patients, 134 patients with 
noninfectious systemic inflammation, and 536 healthy controls (i.e., subjects without known systemic inflam-
mation). The study characteristics are presented in Table 1.
According to our quality assessment, 16 studies were considered as high quality, while 5 studies as moderate 
quality (Supplementary Table S2). Based on visual inspection of the funnel plots (Supplementary Figs. S1–S4), 
some asymmetry could be present, indicating the possible existence of publication bias, which was confirmed 
by the results of Egger’s test (p < 0.1) in one of the analyses (Supplementary Fig. S4). Sensitivity analysis was 
performed for overall SMD presented in the forest plots. The overall SMDs did not vary substantially after 
excluding any individual study, indicating that the results were not driven by one of the analyzed individual 
studies (Tables S3–S6).
Blood levels of MIF in sepsis, noninfectious systemic inflammation, and healthy control 
groups. First, we investigated the change in blood MIF levels in response to sepsis compared to healthy 
Figure 1.  Flowchart of study selection and inclusion.
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Study report [number 
in list of references] Country Study population Population subgroups N (males)
Mean years of age 
(SD)
Mean severity score 
(SD) Deaths N (%)
Ameen et al.37 Kingdom of Saudi Arabia
Severe sepsis and septic 
shock
Survivor 22 (12) 59 (5) APACHE = 25 (4) 0
Nonsurvivor 17 (9) 64 (4) APACHE = 21 (2) 17 (100)
Beishuizen et al.13 The Netherlands
Healthy control 41 (23) 62 (9) NA 0
Multiple trauma 8 (7) 52 (17) APACHE II = 10 (2) 0
Septic shock
32 (20) 64 (13) APACHE II = 15 (6) 11 (34)
Survivor 21 (NR) 61 (11) APACHE II = 12 (5) 0
Nonsurvivor 11 (NR) 67 (14) APACHE II = 18 (5) 11 (100)
Without ARDS 24 (NR) 59 (13) APACHE II = 11 (6) NR
With ARDS 8 (NR) 64 (12) APACHE II = 19 (4) NR
Bozza et al.29 Brazil
Healthy control 11 (NR) NR NA NR
Sepsis 17 (10) 59 (23) APACHE II = 17 (6) 3 (18)
Septic shock 25 (15) 59 (27) APACHE II = 21 (7) 13 (52)
Brenner et al.14 Germany
Healthy control 18 (10) 35 (9) NA 0
Major surgery 28 (12) 62 (14) NR 0
Severe sepsis and septic 
shock
Survivor and nonsur-
vivor 87 (51) 69 (12) NR 44 (51)
Calandra et al.16 Switzerland
Healthy control 6 (NR) Median = 40 NA NR
Sepsis Severe sepsis and septic shock 16 (13) 52 (18) SAPS II = 45 (14) 6 (38)
Chuang et al.38 Taiwan Severe sepsis
Survivor 81 (44)
67 (23) APACHE II = 23 (8)
0
Nonsurvivor 31 (24) 31 (100)
Chuang et al.33 Taiwan Severe sepsis and septic shock
Survivor 109 (68) 71 (15) APACHE II = 22 (8) 0
Died in 48 h 12 (6) 68 (18) APACHE II = 27 (7) 12 (100)
Died after 48 h 32 (21) 74 (12) APACHE II = 25 (8) 32 (100)
de Mendonca-Filho 
et al.35 Brazil Sepsis
Negative microbiology 24 (16) 70 (2) APACHE II = 15 (1) 5 (21)
Positive microbiology 25 (17) 71 (2) APACHE II = 16 (1) 12 (48)
Emonts et al.31 Switzerland and The Netherlands
Healthy control 196 (NR) NR NA NR
Sepsis, severe sepsis, 
and septic shock
Survivor 36 (18) 47 (17) NR 0
Early death 20 (17) 53 (14) NR 20 (100)
Late death 12 (9) 61 (13) NR 12 (100)
Gando et al.28 Japan
Healthy control 10 (NR) NR NA NR
SIRS and sepsis
Without DIC 28 (17) 56 (3) APACHE II = 17 (1) 1 (4)
With DIC 20 (8) 51 (5) APACHE II = 27 (2) 12 (60)
Gao et al.17 USA
Healthy control 53 (NR) NR NA NR
Sepsis 36 (NR) NR NR NR
Sepsis-induced acute 
lung injury 53 (NR) NR NR 19 (36)
Kofoed et al.32 Denmark
Healthy control 10 (NR) NR NA NR
Sepsis 10 (NR) NR NR NR
Leaver et al.25 UK
Healthy control 20 (10) NR NA NR
Severe sepsis and septic 
shock 35 (22) 62 (22) 19 (6) 10 (29)
Lehmann et al.12 Germany
Healthy control 10 (NR) NR NA NR
Nonseptic critically ill 18 (17) 60 (18) SOFA = 2 (1) NR
Severe sepsis 19 (14) 44 (16) SOFA = 10 (2) NR
Lehmann et al.18 Germany
Healthy control 34 (NR) NR NA NR




SOFA = 9 (3) 0
Nonsurvivor 14 (NR) SOFA = 16 (3) 14 (100)
Meawed et al.15 Egypt
Nonseptic systemic 
inflammation 28 (19) 50 (5) NR NR
Sepsis Survivor and nonsur-
vivor
25 (15) 53 (6) APACHE II = 17 (3) 4 (16)
Severe sepsis 27 (16) 63 (7) APACHE II = 20 (3) 15 (56)
Merk et al.26 Canada
Healthy control 85 (NR) NR NA NR
Severe sepsis and septic 
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control subjects. We found 14 studies, reporting data from 579 septic patients and 536 healthy participants that 
could be included in our analysis (Fig. 2). The relative weight of the studies was similar, ranging between 5 and 
8%. As it could be expected based on the function of MIF as a proinflammatory  cytokine11, the blood levels of 
MIF were higher in septic patient groups than in controls in the analyzed studies with SMDs ranging from 0.23 
to 3.51 between the groups. Overall, in septic patient groups blood MIF levels were significantly (p < 0.001) 
higher than in healthy controls with an SMD of 1.47 (95% CI: 0.96–1.97) (Fig. 2).
Next, we studied whether blood MIF levels are increased to a similar or to a different extent in sepsis and in 
noninfectious systemic inflammation. We could include 6 studies in the quantitative analyses, which reported 
data from 257 septic patients and 134 patients with nonseptic systemic inflammation (Fig. 3). In the latter group, 
the cause of systemic inflammation was surgical  intervention12,14,18, multiple  trauma13, and not sepsis-related 
 fever15 or critical  illness30 (see also Table 1). The relative weight of the studies ranged from 11 to 20%. Blood MIF 
levels were higher in septic patient groups than in patient groups with nonseptic systemic inflammation in all 
of the analyzed studies. The overall SMD was 0.94 (95% CI: 0.51–1.38) between the groups (p < 0.001) (Fig. 3).
From three studies which presented blood MIF level values of individual  participants25–27, we could extract 
the data of 101 septic patients and 141 healthy controls. ROC curve analysis of these data revealed an AUC 
of 0.850 (Fig. 4), indicating that blood MIF level measurement shows good sensitivity and specificity for the 
diagnosis of sepsis.
Blood levels of MIF in septic patient groups with different severities of the disease. After 
studying MIF as a potential diagnostic biomarker in sepsis, we also wanted to analyze whether the elevation in 
blood MIF levels can predict the severity of the disease. We found eligible data to address this question from 
two approaches: (1) by comparing patient groups with less and more severe sepsis (e.g., based on the presence of 
organ dysfunction) within the same study; and (2) by comparing survivor and nonsurvivor septic patient groups 
within the same study.
We found 11 studies, in which blood MIF levels were reported in different severity groups of sepsis. The 
groups with more severe form of the disease were categorized based on different criteria in the different stud-
ies, which included the presence of one of the following conditions: organ damage (viz., pulmonary, kidney or 
adrenal gland dysfunction)13,17,34,36, septic  shock16,29, early  fatality31,33, severe  sepsis15, disseminated intravascular 
 coagulopathy28, and positive blood  culture35 (for details, see Table 1). In the majority of the studies, higher clini-
cal severity scores were also reported in the patient groups with more severe disease. In total, 347 patients were 
included in the more severe and 274 patients in the less severe septic groups. The relative weight of the studies 
was between 7 and 11%. Our meta-analysis revealed that blood MIF level was significantly (p < 0.001) higher in 
the more severe forms of sepsis with an overall SMD of 0.84 (95% CI: 0.45–1.24) (Fig. 5).
Blood MIF levels were compared between survivors and nonsurvivors of sepsis in 11 studies, including 447 
and 257 patients in the groups, respectively. The studies had similar relative weights, ranging from 7 to 11%. 
For the meta-analysis, SMD was calculated by subtracting the mean blood MIF level of sepsis survivors from 
that of sepsis nonsurvivors. We found that the overall SMD was significantly (p < 0.001) higher than zero (0.75, 
95% CI: 0.40–1.11) (Fig. 6), indicating that blood MIF levels were markedly higher in nonsurvivors than in 
survivors of sepsis.
Table 1.  Characteristics of participants in the studies included in the meta-analysis. *MIF levels were reported 
for 29 septic and 10 survivor patients. ARDS adult respiratory distress syndrome, APACHE acute physiology 
and chronic health evaluation score, DIC disseminated intravascular coagulation, NA not applicable, NR not 
reported, SAPS simplified acute physiology score, SIRS systemic inflammatory response syndrome, SOFA 
sequential (sepsis-related) organ failure assessment score.
Study report [number 
in list of references] Country Study population Population subgroups N (males)
Mean years of age 
(SD)
Mean severity score 
(SD) Deaths N (%)
Miyauchi et al.34 Japan Sepsis
Normal adrenal 
response 22 (14) 63 (17) APACHE II = 26 (6) 6 (27)
Adrenal insufficiency 19 (16) 66 (15) APACHE II = 26 (10) 6 (32)
Payen et al.36 France Severe sepsis and septic shock
Without acute kidney 
injury 47 (30) Median = 60 Median SOFA = 5 6 (12)
Mild acute kidney 
injury 75 (47) Median = 61 Median SOFA = 7 20 (26)
Severe acute kidney 
injury 54 (34) Median = 63 Median SOFA = 10 22 (41)
Pohl et al.30 Germany
Healthy control 10 (NR) NR NA NR
Nonseptic critically ill 42 (28) 69 (13) APACHE II = 24 (9) 35 (83)
Severe sepsis and septic 
shock 30 (19) 69 (11) APACHE II = 26 (9) 13 (43)
Wiersinga et al.27 Thailand
Healthy controls 32 (23) 41 (9) NA NR
Sepsis Survivor and nonsur-vivor 34* (17) 52 (16) NR 15* (44)
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Discussion
In the present study, we show that blood MIF level can be a useful biomarker in sepsis for both diagnostic and 
prognostic purposes, to the best of our knowledge for the first time, with the meta-analysis of the available data 
in the literature. The main new findings of our meta-analyses are that blood MIF levels are increased to a greater 
extent in sepsis than in systemic inflammation of noninfectious origins and that MIF levels are higher in the 
more severe forms of sepsis and in nonsurvivors than in less severe forms and survivors, respectively.
Sepsis affects tens of millions of patients annually and it constitutes an ongoing challenge for the healthcare 
system due to its high mortality and economic burden, especially in its severe  forms39. A recent analysis showed 
that in intensive care units, hospital-acquired sepsis is frequent and accounts for a high (over 40%) mortality 
 rate40. In order to improve outcomes, it is required to further develop the approaches for early diagnosis and 
implementation of adequate treatment of sepsis. The use of biomarkers can help to achieve these goals. As a 
consequence, a plethora of potential biomarkers was evaluated for the diagnosis and prognosis of sepsis (for a 
recent review,  see6).
As an early step in the development of systemic inflammation, the activation of innate immune cells leads to 
the production of inflammatory  cytokines41. MIF is one of these proinflammatory cytokines, which was originally 
thought to be produced in the pituitary gland and T lymphocytes, but later it was found to be expressed in a 
variety of cells, including endothelial cells, eosinophils, and  macrophages42. Upon stimulation by endotoxins and 
cytokines, macrophages release MIF, which acts in concert with other cytokines (e.g., tumor necrosis factor-α) 
and promotes the acute inflammatory  response43. In humans, high MIF concentrations were first found in the 
alveolar airspaces of patients with acute respiratory distress  syndrome44, which is a frequent complication in 
severe (often fatal) forms of  sepsis45. Since then, several studies showed that blood MIF level is increased in 
different forms of systemic  inflammation13,16,26. As a consequence, MIF was considered amongst the potential 
diagnostic and prognostic biomarkers in  sepsis6,7,46.
Figure 2.  Forest plot of standardized mean differences (SMDs) in blood levels of macrophage migration 
inhibitory factor (MIF) between septic patients and healthy controls. Here, and in Figs. 3, 5, and 6 black 
diamonds represent the SMD for each study, while the left and right horizontal arms of the diamonds indicate 
the corresponding 95% confidence intervals (CIs). The size of the gray box surrounding the diamond is 
proportional to the relative weight of the study. The open rhombus on the bottom represents the average SMD 
calculated from the SMDs of all individual studies. The left and right vertices of the rhombus represent the CIs 
of the average SMD, while the vertical diagonal and the dashed line indicate the average SMD of all studies in 
the forest plot. A negative SMD indicates higher MIF levels in healthy controls, whereas an SMD greater than 
zero indicates increased MIF levels in sepsis. SD standard deviation.
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It has not been fully clarified, however, whether septic and nonseptic systemic inflammation can be 
Figure 3.  Forest plot of standardized mean differences (SMDs) in blood levels of macrophage migration 
inhibitory factor (MIF) between septic patients and patients with systemic inflammation due to noninfectious 
causes. CI confidence interval, SD standard deviation.
Figure 4.  Receiver operating characteristic (ROC) curve analysis of the diagnostic performance of blood 
macrophage migration inhibitory factor (MIF) levels in sepsis. The individual data of septic patients (N = 101) 
and healthy controls (N = 141) were extracted from previously published  studies25–27. The area under the blue 
ROC curve was 0.850. The diagonal red line serves as a reference line corresponding to the ROC curve of a 
diagnostic test that randomly classifies the condition (i.e., a test that has no diagnostic ability).
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distinguished based on the different extent of elevation in blood MIF levels. Some authors found that MIF levels 
were higher in sepsis than in noninfectious systemic  inflammation13–15,30, whereas others did not find a significant 
difference in MIF levels between the two forms of systemic  inflammation12,18. In the present study, we compared 
MIF levels in sepsis and in noninfectious inflammation of different origins (see Table 1, for details) in 257 and 
134 patients, respectively, and showed that blood MIF concentration is markedly increased in case of sepsis 
compared to nonseptic systemic inflammation. These findings suggest that MIF can be used as a diagnostic tool 
to distinguish sepsis from other systemic inflammatory diseases. It can be assumed that the production of MIF 
is more enhanced when the triggering agent of the inflammatory reaction is a microbial pathogen than when 
it is a damage-associated molecular pattern (DAMP). Indeed, it has been shown that DAMPs and pathogen-
associated molecular patterns (PAMPs) activate the immune system differently, in particular, DAMPs produce 
weaker innate immune activation than PAMPs, which also involves more pronounced production of inflamma-
tory cytokines in case of  PAMPs47. In line with these findings in experimental models, the increased MIF levels 
in multiple trauma patients were further elevated when an infection developed, suggesting that MIF may be an 
indicator of secondary  infection48,49.
The prognostic value of MIF is also a controversial issue. In the study by Beishuizen et al.13, MIF levels tended 
to be higher in septic shock patients who developed acute respiratory distress syndrome than in those who did not 
(p = 0.115). MIF levels seemed higher in septic shock than in severe sepsis in the fundamental study by Calandra 
et al.16, but the difference between the groups was not significant. Furthermore, MIF levels did not differ between 
survivors and nonsurvivors of severe  sepsis18, contradicting earlier reports about higher circulating MIF levels in 
nonsurvivor sepsis  patients13,14,50, and about its association with fatal outcome in  sepsis29. In the present work, we 
showed that MIF levels were significantly higher in the groups with worse prognosis, indicating that MIF can be a 
useful biomarker to predict the severity and the outcome of the disease. It can be assumed that in severe forms of 
sepsis an overt inflammatory reaction develops, which also involves a pronounced cytokine storm and excessive 
production of MIF. As a result, the pro- and anti-inflammatory processes become unbalanced, the inflammatory 
response loses its adaptive biological function, and turns into an unregulated, destructive process, which is no 
longer beneficial, but instead harmful for the host. The role of MIF can be crucial in the disruption of the pro- 
and anti-inflammatory balance, because MIF counter-regulates the anti-inflammatory and immunosuppressive 
effects of  glucocorticoids51–53. Based on this scenario, it can be also understood, why neutralization of MIF with 
antibodies improved the outcome in animal models of severe systemic  inflammation16,54,55. Whether MIF can be 
used as a therapeutic target and marker in septic patients, as proposed by different  authors16,56, remains subject 
for future research.
Figure 5.  Forest plot of standardized mean differences (SMDs) in blood levels of macrophage migration 
inhibitory factor (MIF) between patients with more severe and less severe forms of sepsis. CI confidence 
interval, SD standard deviation.
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Some limitations of our study should be noted. Due to the nature of the meta-analysis method, we have 
studied the reported mean MIF levels in patient groups, instead of MIF levels in individual patients. The latter 
approach would certainly allow one to draw firmer conclusions about the association between MIF and the diag-
nosis and prognosis of sepsis, but that would require access to the original data of the analyzed articles, which 
was not feasible. Due to lack of data, we could not perform a network meta-analysis to compare the performance 
of MIF with other frequently used inflammatory biomarkers, hence we cannot make any comment on its real 
value compared to others.
In our study, we compared blood MIF level in septic patients to that of either healthy controls or patients with 
nonseptic systemic inflammation. This method can be useful to identify potential diagnostic biomarkers, but it 
cannot be used to determine the diagnostic performance of MIF. To evaluate diagnostic test performance, the 
pre- and post-test probabilities are required, but “pre-test probability” amongst healthy controls is 0 (and thus 
“post-test probability” is also 0). The diagnostic performance of MIF is likely to be lower when distinguishing 
noninfectious systemic inflammation from sepsis, because of the smaller sample size (391 vs. 1115) and the lower 
SMD (0.94 vs. 1.47) compared to the analysis of healthy controls and septic patients.
An ideal study would include patients who were clinically suspected of sepsis, and compare their MIF lev-
els with confirmed diagnosis of sepsis as this would allow assessment of the post-test probability of this test. 
Unfortunately, the analyzed studies did not have such ideal design. There were only two studies which included 
patients with suspicion of  sepsis29,30, but those did not report the diagnostic performance of MIF only its good 
performance for the prediction of mortality. In another study, MIF levels between septic patients and healthy 
volunteers were compared and ROC curve analysis was performed, which indicated excellent sensitivity and 
specificity for MIF (AUC of 0.99)26. Further, in patients with clinical diagnosis of sepsis, MIF levels showed good 
performance in the prediction of positive bacterial cultures (AUC of 0.823)35.
For the assessment of diagnostic performance, the separation between positive and negative cases is important 
as it indicates the potential for false positive and false negative results. This is best assessed by ROC curve analysis, 
which requires individual patient data. As an attempt to perform ROC curve analysis, we extracted individual 
patient data from eligible  papers25–27, and showed that blood MIF level has good diagnostic performance to 
distinguish septic patients from healthy controls. However, we could not collect sufficient data to perform the 
ROC curve analysis for the diagnostic value of MIF between infectious and noninfectious systemic inflammation 
and for its prognostic performance. Therefore, to exclude the possibility that mean levels of MIF simply differed 
Figure 6.  Forest plot of standardized mean differences (SMDs) in blood levels of macrophage migration 
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significantly between the cohorts examined, in future studies additional ROC curve analyses are warranted to 
support our findings about the diagnostic and prognostic ability of MIF.
Another important issue with the comparison between sepsis and nonseptic systemic inflammation is that 
in 3 of the analyzed  studies12,13,18 the clinical severity scores were significantly higher in septic than in nonseptic 
patients. Since we also showed that blood MIF levels are higher in more severe forms of sepsis than in less severe 
forms (Fig. 5), it cannot be excluded that the difference in MIF levels between septic and nonseptic patients was 
also influenced by the higher severity scores in the septic patients in some of the studies.
The studied population of patients was quite diverse and statistical, methodological, and medical differences 
in study design could all contribute to the considerably high between-study heterogeneity (indicated by an I2 of 
70–90%), as observed in our analysis (Figs. 2, 3, 5, 6). To account for the presence of heterogeneity, we used the 
random-effects model in all forest plots of our meta-analyses.
In the analyzed studies, blood MIF levels between patients’ groups were compared within the same study 
and the difference was included in the forest plot. Since the reported MIF values differed substantially among 
the analyzed studies, ranging between 121 ng/l32 and 46,829 ng/l18 in healthy controls (Fig. 2), SMDs had to be 
used to mitigate methodological differences in MIF level measurements. Consequently, in the present analysis 
we could not determine a specific cut-off MIF level which would be a diagnostic or prognostic threshold in 
sepsis. The most convincing method to obtain direct evidence for the diagnostic and prognostic performance 
of MIF in sepsis would be to conduct high-quality, targeted clinical trials in a broad population of patients who 
are clinically suspected of sepsis. Until such or similar trials are conducted, we are restricted to use different (not 
so direct) approaches, e.g., meta-analyses. In the design of future studies, other classical and novel biomarkers, 
perhaps in combination with MIF, may be also considered, for example, neutrophil CD64, which was superior 
to procalcitonin for the identification of sepsis according to a recent meta-analysis57.
Despite the mentioned limitations, we believe that the size of the analyzed sample (N = 1876) was big enough 
to mitigate the methodological differences among the studies, therefore we may draw, at least some, conclusions 
about the potential diagnostic and prognostic value of MIF in septic patients.
Conclusions
To the best of our knowledge, this is the first meta-analysis to show that blood MIF levels could have diagnostic 
ability to differentiate between infectious and noninfectious systemic inflammation and could have prognostic 
value for the outcome of sepsis. Our results can also serve as an encouraging basis for the design of high-quality, 
targeted clinical studies aiming to determine the real diagnostic and prognostic performance of MIF level meas-
urements in sepsis.
Data availability
All data generated or analyzed during this study are included in this published article and its supplementary 
information.
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